| Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
|
MELLIN GW, 1962, NEW ENGL J MED, V267, P1184 MELLIN GW, 1962, NEW ENGL J MED, V267, P1238 LENZ W, 1961, DEUT MED WOCHENSCHR, V86, P2555 LENZ W, 1962, DEUT MED WOCHENSCHR, V87, P1232 KUNZ W, 1956, ARZNEIMITTEL-FORSCH, V6, P426 SHESKIN J, 1965, LEPROSY REV, V36, P183 WIEDEMANN HR, 1961, MED WELT, V37, P1863 BECKMANN R, 1962, ARZNEIMITTEL-FORSCH, V12, P1095 |
Nodes: 2685,
Authors: 6203,
Journals: 662,
Outer References: 16023,
Words: 3995
Collection span: 1956 - 2004
View: Overview. Sorted by year, source, volume, issue, page.
Page 9: 1 2 3 4 5 6 7 8 9
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
|---|---|---|---|---|---|
| 2401 | 0 | 1 | 2401 2003 BONE MARROW TRANSPLANTATION 31(11):1067-1067 Alam AR Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT - Reply to the letter by V Pitini | 0 | 0 |
| 2402 | 13 | 35 | 2402 2003 BONE MARROW TRANSPLANTATION 32(2):165-170 Kulkarni S; Powles R; Sirohi B; Treleaven J; Saso R; Horton C; Atra A; Ortin M; Rudin C; Goyal S; Sankpal S; Meller S; Pinkerton CR; Mehta J; Singhal S Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease | 0 | 1 |
| 2403 | 6 | 6 | 2403 2003 BONE MARROW TRANSPLANTATION 32(3):343-343 Milone JH; Prates V; Bordone J; Napal J; Garcia C Response to single-agent thalidomide and eligibility to undergo autotransplant for patients with multiple myeloma refractory to VAD | 0 | 0 |
| 2404 | 11 | 28 | 2404 2003 BONE MARROW TRANSPLANTATION 32(6):587-592 Ghobrial IM; Dispenzieri A; Bundy KL; Gastineau DA; Rajkumar SV; Therneau TM; Lacy MQ; Witzig TE; Litzow MR; Christensen BR; Hayman S; Pribula CG; Gertz MA Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma | 1 | 1 |
| 2405 | 0 | 0 | 2405 2003 BRITISH JOURNAL OF CANCER 88:S28-S28 Dalgleish A; Schey S; Jones R; Raj K; Dredge K; Streetly M; Marriott B Thalidomide analogues CC-5013 and CC-4047 induce T cell activation and IL-12 production in patients with both solid tumours and relapsed and refractory multiple myeloma. | 0 | 0 |
| 2406 | 0 | 0 | 2406 2003 BRITISH JOURNAL OF CANCER 88:S46-S46 Malpas J; Chaplin T; Sanmugathasan A; Liu W In vitro activity of S-thalidomide against multiple myeloma cells: A gene and protein expression profile. | 0 | 0 |
| 2407 | 8 | 20 | 2407 2003 BRITISH JOURNAL OF CANCER 88(6):822-827 Drake MJ; Robson W; Mehta P; Schofield I; Neal DE; Leung HY An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer | 3 | 9 |
| 2408 | 4 | 9 | 2408 2003 BRITISH JOURNAL OF DERMATOLOGY 148(3):601-602 Worm M; Kolde G Schnitzler's syndrome: successful treatment of two patients using thalidomide | 0 | 0 |
| 2409 | 5 | 11 | 2409 2003 BRITISH JOURNAL OF DERMATOLOGY 148(5):1060-1061 Tjiu JW; Hsiao CH; Tsai TF Cutaneous Rosai-Dorfman disease: remission with thalidomide treatment | 0 | 0 |
| 2410 | 0 | 0 | 2410 2003 BRITISH JOURNAL OF DERMATOLOGY 149:81-81 Strauss RM; Bate J; Clayton T; Gooi J; Darling J; Newton-Bishop JA A child with laryngo-onycho-cutaneous syndrome successfully treated with thalidomide | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2411 | 11 | 14 | 2411 2003 BRITISH JOURNAL OF DERMATOLOGY 149(2):432-433 Dobson CM; Parslew RA Exacerbation of psoriasis by thalidomide in Behcet's syndrome | 0 | 0 |
| 2412 | 19 | 50 | 2412 2003 BRITISH JOURNAL OF HAEMATOLOGY 120(1):18-26 Cavenagh JD; Oakervee H; UK Myeloma Forum; BSCH Haematology Oncology Task For Thalidomide in multiple myeloma: Current status and future prospects | 12 | 15 |
| 2413 | 5 | 12 | 2413 2003 BRITISH JOURNAL OF HAEMATOLOGY 121(1):101-103 Steurer M; Sudmeier I; Stauder R; Gastl G Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha | 3 | 5 |
| 2414 | 3 | 5 | 2414 2003 BRITISH JOURNAL OF HAEMATOLOGY 121(1):191-192 Younis TH Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma | 1 | 2 |
| 2415 | 4 | 12 | 2415 2003 BRITISH JOURNAL OF HAEMATOLOGY 121(5):768-771 Anagnostopoulos A; Weber D; Rankin K; Delasalle K; Alexanian R Thalidomide and dexamethasone for resistant multiple myeloma | 11 | 16 |
| 2416 | 4 | 7 | 2416 2003 BRITISH JOURNAL OF HAEMATOLOGY 122(1):159-160 Santos AB; Llamas P; Roman A; Prieto E; de Ona R; de Velasco JF; Tomas JF Evaluation of thrombophylic states in myeloma patients receiving thalidomide: A reasonable doubt | 1 | 1 |
| 2417 | 5 | 6 | 2417 2003 BRITISH JOURNAL OF HAEMATOLOGY 122(1):160-161 Harris E; Behrens J; Samson D; Rahemtulla A; Russell NH; Byrne JL Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia | 2 | 3 |
| 2418 | 19 | 40 | 2418 2003 BRITISH JOURNAL OF HAEMATOLOGY 122(4):607-616 Kropff MH; Lang N; Bisping G; Domine N; Innig G; Hentrich M; Mitterer M; Sudhoff T; Fenk R; Straka C; Heinecke A; Koch OM; Ostermann H; Berdel WE; Kienast J Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma | 4 | 8 |
| 2419 | 4 | 10 | 2419 2003 BRITISH JOURNAL OF HAEMATOLOGY 123(2):305-308 Thompson MA; Witzig TE; Kumar S; Timm MM; Haug J; Fonseca R; Greipp PR; Lust JA; Rajkumar SV Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma | 2 | 4 |
| 2420 | 9 | 20 | 2420 2003 BRITISH JOURNAL OF HAEMATOLOGY 123(3):436-441 Thomas DA; Estey E; Giles FJ; Faderl S; Cortes J; Keating M; O'Brien S; Albitar M; Kantarjian H Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2421 | 1 | 1 | 2421 2003 BRITISH JOURNAL OF HAEMATOLOGY 123(3):563-563 Younis T; Alam A; Paplham P; Spangenthal E; McCarthy P Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma (vol 121, pg 191, 2003) | 0 | 1 |
| 2422 | 1 | 3 | 2422 2003 BRITISH JOURNAL OF HAEMATOLOGY 123(4):747-748 Mileshkin L; Prince HM; Seymour JF; Biagi JJ Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide | 0 | 0 |
| 2423 | 0 | 3 | 2423 2003 BRITISH JOURNAL OF HAEMATOLOGY 123(4):748-748 Luminari S; Federico M; Baldini L Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide - Response to Mileshkin et al. | 0 | 0 |
| 2424 | 0 | 1 | 2424 2003 BRITISH MEDICAL JOURNAL 327(7418):767-767 Burgermeister J Head of German medicines body likens HRT to thalidomide | 0 | 0 |
| 2425 | 5 | 34 | 2425 2003 CANCER 97(5):1234-1241 Cortes J; Kantarjian H; Albitar M; Thomas D; Faderl S; Koller C; Garcia-Manero G; Giles F; Andreeff M; O'Brien S; Keating M; Estey E A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome | 1 | 5 |
| 2426 | 5 | 27 | 2426 2003 CANCER CHEMOTHERAPY AND PHARMACOLOGY 52:S16-S23 Hashimoto Y Structural development of synthetic retinoids and thalidomide-related molecules | 0 | 0 |
| 2427 | 0 | 0 | 2427 2003 CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION 12(11):1288S-1288S Hsu C; Chen HN; Chen LT; Wu CY; Hsieh FJ; Cheng AL Use of power Doppler sonography and circulating angiogenic factors to assess the potential antiangiogenic effect of thalidomide in hepatocellular carcinoma. | 0 | 0 |
| 2428 | 22 | 28 | 2428 2003 CANCER RESEARCH 63(3):593-599 Marriott JB; Clarke IA; Czajka A; Dredge K; Childs K; Man HW; Schafer P; Govinda S; Muller GW; Stirling DI; Dalgleish AG A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins | 6 | 13 |
| 2429 | 21 | 31 | 2429 2003 CANCER RESEARCH 63(12):3189-3194 Ng SSW; Gutschow M; Weiss M; Hauschildt S; Teubert U; Hecker TK; Luzzio FA; Kruger EA; Eger K; Figg WD Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues | 3 | 5 |
| 2430 | 5 | 39 | 2430 2003 CELLULAR AND MOLECULAR BIOLOGY 49(7):1117-1124 Ezell TN; Maloney N; Githua JW; Taylor LD Exposure to the anti-TNF-alpha drug thalidomide induces apoptotic cell death in human T leukemic cells | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2431 | 9 | 31 | 2431 2003 CHEMICAL & PHARMACEUTICAL BULLETIN 51(9):1098-1102 Suizu M; Muroya Y; Kakuta H; Kagechika H; Tanatani A; Nagasawa K; Hashimoto Y Cyclooxygenase inhibitors derived from thalidomide | 2 | 2 |
| 2432 | 0 | 0 | 2432 2003 CIRCULATION 108(17):170-170 Kirchmair R; Murayama T; Rittig K; Tietz A; Walter D; Schratzberger P; Weinberg DH; Ropper AH; Isner JM Therapeutic angiogenesis inhibits and rescues chemotherapy induced peripheral neuropathy: Taxol, cisplatin and thalidomide induced injury vasa nervorum is ameliorated by VEGF gene therapy | 0 | 0 |
| 2433 | 4 | 12 | 2433 2003 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 21(2):272-272 Meaux-Ruault N; Magy N; Gil H; Dupond JL Efficacy of thalidomide in refractory adult Still's disease: A new case report | 0 | 0 |
| 2434 | 30 | 38 | 2434 2003 CLINICAL CANCER RESEARCH 9(5):1680-1688 Lu J; Palmer BD; Kestell P; Browett P; Baguley BC; Muller G; Ching LM Thalidomide metabolites in mice and patients with multiple myeloma | 5 | 6 |
| 2435 | 0 | 0 | 2435 2003 CLINICAL CANCER RESEARCH 9(14):5429-5429 Ching LM; Baguley BC; Kestell P; Palmer BD; Lu J Correspondence re: J. Lu et al., Thalidomide metabolites in mice and patients with multiple myeloma. Clin. Cancer Res., 9 : 1680-1688, 2003. - Reply | 0 | 0 |
| 2436 | 8 | 8 | 2436 2003 CLINICAL CANCER RESEARCH 9(14):5429-5429 Zhou SF Correspondence re: J. Lu et al., Thalidomide metabolites in mice and patients with multiple myeloma. Clin. Cancer Res., 9 : 1680-1688, 2003. | 0 | 0 |
| 2437 | 0 | 0 | 2437 2003 CLINICAL CANCER RESEARCH 9(16):6150S-6150S Baas P; Haringhuizen A; Boogerd W; Dalesio O; Van Zandwijk N Thalidomide in malignant pleural mesothelioma: Results of a phase II study. | 0 | 0 |
| 2438 | 16 | 25 | 2438 2003 CLINICAL LYMPHOMA 3(4):241-246 Seldin DC; Choufani EB; Dember LM; Wiesman JF; Berk JL; Falk RH; O'Hara C; Fennessey S; Finn KT; Wright DG; Skinner M; Sanchorawala V Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis | 4 | 8 |
| 2439 | 9 | 21 | 2439 2003 CLINICAL LYMPHOMA 3(4):247-248 Blade J; Rosinol L Thalidomide: A step forward in the treatment of malignant monoclonal gammopathies | 0 | 0 |
| 2440 | 5 | 20 | 2440 2003 CLINICAL LYMPHOMA 4(1):32-35 Zangari M; Barlogie B; Thertulien R; Jacobson J; Eddleman P; Fink L; Fassas A; Van Rhee F; Talamo G; Lee CK; Tricot G Thalidomide and deep vein thrombosis in multiple myeloma: Risk factors and effect on survival | 1 | 4 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2441 | 0 | 0 | 2441 2003 CLINICAL PHARMACOLOGY & THERAPEUTICS 73(2):P55-P55 Gordon SM; Wahl SM; Picco C; Dionne RA Safety and tolerability and absorption of topical thalidomide. | 0 | 0 |
| 2442 | 166 | 221 | 2442 2003 CLINICAL THERAPEUTICS 25(2):342-395 Matthews SJ; McCoy C Thalidomide: A review of approved and investigational uses | 2 | 5 |
| 2443 | 52 | 86 | 2443 2003 CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 46:S49-S57 Macpherson GR; Franks M; Tomoaia-Cotisel A; Ando Y; Price DK; Figg WD Current status of thalidomide and its role in the treatment of metastatic prostate cancer | 0 | 1 |
| 2444 | 13 | 38 | 2444 2003 CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 46:S59-S65 Amato RJ Thalidomide therapy for renal cell carcinoma | 0 | 1 |
| 2445 | 44 | 59 | 2445 2003 CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT 6(1):92-99 Meierhofer C; Wiedermann CJ New insights into the pharmacological and toxicological effects of thalidomide | 3 | 3 |
| 2446 | 11 | 18 | 2446 2003 DERMATOLOGY 206(4):381-383 Kolivras A; De Maubeuge J; Andre J; Song M Thalidomide in refractory vulvar ulcerations associated with Crohn's disease | 1 | 1 |
| 2447 | 2 | 3 | 2447 2003 DIABETES CARE 26(4):1322-1323 Pathak RD; Jayaraj K; Blonde L Thalidomide-associated hyperglycemia and diabetes - Case report and review of literature | 0 | 0 |
| 2448 | 6 | 42 | 2448 2003 DIABETOLOGIA 46(12):1669-1675 Bosco AA; Lerario AC; Santos RF; Wajchenberg BL Effect of thalidomide and rosiglitazone on the prevention of diabetic retinopathy in streptozotocin-induced diabetic rats | 1 | 1 |
| 2449 | 21 | 37 | 2449 2003 DRUG METABOLISM AND DISPOSITION 31(4):469-475 Miyata M; Tamura E; Motoki K; Nagata K; Yamazoe Y Thalidomide-induced suppression of embryo fibroblast proliferation requires CYP1A1-mediated activation | 2 | 2 |
| 2450 | 0 | 0 | 2450 2003 DRUG METABOLISM AND DISPOSITION 31(8):1072-1072 Miyata M CYP1A1-mediated activation of thalidomide and suppression of embryo fibroblast proliferation - Reply | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2451 | 5 | 10 | 2451 2003 DRUG METABOLISM AND DISPOSITION 31(8):1072-1072 Zhou SF CYP1A1-mediated activation of thalidomide and suppression of embryo fibroblast proliferation | 0 | 0 |
| 2452 | 0 | 0 | 2452 2003 EUROPEAN JOURNAL OF CANCER 39(7):854-854 [Anon] Thalidomide on trial | 0 | 0 |
| 2453 | 14 | 33 | 2453 2003 EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY 15(9):951-957 Muriel P; Fernandez-Martinez E; Perez-Alvarez V; Lara-Ochoa F; Ponce S; Garcia J; Shibayama M; Tsutsumi V Thalidomide ameliorates carbon tetrachloride induced cirrhosis in the rat | 0 | 1 |
| 2454 | 1 | 6 | 2454 2003 EUROPEAN JOURNAL OF HAEMATOLOGY 70(3):198-199 Vicari P; Ribas C; Sampaio M; Arantes AM; Yamamoto M; Reis JB; Segreto RA; Bordin JO; Colleoni GWB Can thalidomide be effective to treat plasma cell leptomeningeal infiltration? | 0 | 0 |
| 2455 | 0 | 0 | 2455 2003 EXPERIMENTAL HEMATOLOGY 31(7):198-198 Moutouh-De Parseval L; Glezer E; Corral L; Galliher A; Wu J; Brady H; Mercurio F; Chan K Immunomodulatory thalidomide analogs modulate hematopoietic stem cell developmental pathways | 0 | 0 |
| 2456 | 74 | 144 | 2456 2003 EXPERT OPINION ON INVESTIGATIONAL DRUGS 12(7):1211-1225 Fanelli M; Sarmiento R; Gattuso D; Carillio G; Capaccetti B; Vacca A; Roccaro AM; Gasparini G Thalidomide: a new anticancer drug? | 2 | 6 |
| 2457 | 0 | 0 | 2457 2003 FASEB JOURNAL 17(7):C124-C124 Dredge K; Marriott JB; Todryk SM; Klaschka D; Horsfall R; Dalgleish A The role of thalidomide-related IMiDs in the induction of innate and adaptive anti-tumor immunity | 0 | 0 |
| 2458 | 0 | 0 | 2458 2003 GASTROENTEROLOGY 124(4):A10-A10 Jin SH; Kim WH; Kim TI; Yang KM; Shin SK; Lee SK; Park SJ; Choi CH; Lee WJ Thalidomide destabilizes cyclooxygenase-2 mRNA by inhibiting p38 mitogen-activated protein kinase and cytoplasmic shuttling of HuR | 0 | 0 |
| 2459 | 0 | 0 | 2459 2003 GASTROENTEROLOGY 124(4):A336-A336 Kim YS; Kim JS; Jung HC; Song IS The effects of thalidomide on NF-R activity and TNF-production stimulated with lipopolysaccharide in a human colonic epithelial cell line ka | 0 | 0 |
| 2460 | 0 | 0 | 2460 2003 GASTROENTEROLOGY 124(4):A525-A525 Gupta P; Andrew H; Kirschner BS Thalidomide therapy for pediatric patients with refractory Crohn's disease not responding to infliximab | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2461 | 3 | 10 | 2461 2003 HAEMATOLOGICA 88(5):597-599 Patriarca F; Sperotto A; Prosdocimo S; Geromin A; Zaja F; Fanin R Thalidomide before autologous stem cell transplantation in VAD-refractory multiple myeloma patients | 0 | 0 |
| 2462 | 4 | 10 | 2462 2003 HAEMATOLOGICA 88(8):958-960 Corso A; Lorenzi A; Zapposodi P; Invernizzi R; Vanelli L; Lazzarino M Early changes in bone marrow morphology induced by thalidomide in patients with refractory myeloma | 0 | 0 |
| 2463 | 4 | 10 | 2463 2003 HAEMATOLOGICA 88(12):1432-1433 Offidani M; Marconi M; Corvotta L; Olivieri A; Catarini M; Leoni P Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study | 0 | 1 |
| 2464 | 6 | 15 | 2464 2003 INTERNAL MEDICINE 42(7):550-551 Dan K Thalidomide as a targeted therapy for multiple myeloma | 0 | 0 |
| 2465 | 5 | 10 | 2465 2003 INTERNAL MEDICINE 42(7):605-608 Hayashi T; Yamaguchi I; Saitoh H; Takagi M; Nonaka Y; Nomura T Thalidomide treatment for immunoglobulin D multiple myeloma in a patient on chronic hemodialysis | 1 | 1 |
| 2466 | 16 | 42 | 2466 2003 INTERNATIONAL IMMUNOPHARMACOLOGY 3(10-11):1447-1456 Karrow NA; Guo TL; Zhang LX; McCay JA; Musgrove DL; Peachee VL; Germolec DR; White KL Thalidomide modulation of the immune response in female B6C3F1 mice: a host resistance study | 0 | 0 |
| 2467 | 12 | 39 | 2467 2003 INTERNATIONAL JOURNAL OF DERMATOLOGY 42(5):372-375 Alfadley A; Al-Hawsawi K; Thestrup-Pedersen K; Al-Aboud K Treatment of prurigo nodularis with thalidomide: a case report and review of the literature | 0 | 0 |
| 2468 | 6 | 40 | 2468 2003 INTERNATIONAL JOURNAL OF HEMATOLOGY 78(5):443-449 Ural AU; Yilmaz MI; Avcu F; Pekel A; Zerman M; Nevruz O; Sengul A; Yalcin A The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide | 0 | 1 |
| 2469 | 7 | 20 | 2469 2003 INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 11(6):785-790 Li XP; Liu XY; Wang J; Wang ZL; Jiang W; Reed E; Zhang Y; Liu YL; Li QQ Effects of thalidomide on the expression of angiogenesis growth factors in human A(549) lung adenocarcinoma cells | 0 | 0 |
| 2470 | 5 | 41 | 2470 2003 INTERNATIONAL JOURNAL OF ONCOLOGY 22(1):165-173 Yata K; Otsuki T; Kurebayashi J; Uno M; Fujii T; Yawata Y; Takata A; Hyodoh F; Sugihara T Expression of angiogenic factors including VEGFs and the effects of hypoxia and thalidomide on human myeloma cells | 2 | 3 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2471 | 13 | 23 | 2471 2003 INTERNATIONAL JOURNAL OF ONCOLOGY 23(6):1651-1655 Kaicker S; McCrudden KW; Beck L; New T; Huang JZ; Frischer JS; Serur A; Kadenhe-Chiweshe A; Yokoi A; Kandel JJ; Yamashiro DJ Thalidomide is anti-angiogenic in a xenograft model of neuroblastoma | 0 | 0 |
| 2472 | 17 | 32 | 2472 2003 INVESTIGATIONAL NEW DRUGS 21(3):359-366 Dal Lago L; Richter MF; Cancela AI; Fernandes SA; Jung KT; Rodrigues AC; Dalla Costa T; Di Leone LP; Schwartsmann G Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer | 0 | 0 |
| 2473 | 4 | 9 | 2473 2003 JCR-JOURNAL OF CLINICAL RHEUMATOLOGY 9(2):96-98 Ching DWT; McClintock A; Beswick F Successful treatment with low-dose thalidomide in a patient with both Behcet's disease and complex regional pain syndrome type I - Case report | 0 | 0 |
| 2474 | 0 | 0 | 2474 2003 JOURNAL OF BONE AND MINERAL RESEARCH 18:S310-S310 Bose N; Bergemann H; Westendorf JJ; Rajkumar SV; Masellis AM Expression of alternatively spliced Runx2 in multiple myeloma patients and a shift in expression in response to thalidomide treatment. | 0 | 0 |
| 2475 | 59 | 70 | 2475 2003 JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES 785(1):165-173 Zhou SF; Lia Y; Kestell P; Paxton JW Determination of thalidomide in transport buffer for Caco-2 cell monolayers by high-performance liquid chromatography with ultraviolet detection | 0 | 0 |
| 2476 | 7 | 22 | 2476 2003 JOURNAL OF CLINICAL ONCOLOGY 21(1):16-19 Weber D; Rankin K; Gavino M; Delasalle K; Alexanian R Thalidomide alone or with dexamethasone for previously untreated multiple myeloma | 29 | 55 |
| 2477 | 6 | 15 | 2477 2003 JOURNAL OF CLINICAL ONCOLOGY 21(11):2211-2214 Loprinzi C; Rajkumar SV Why not start with thalidomide? | 0 | 1 |
| 2478 | 4 | 37 | 2478 2003 JOURNAL OF CLINICAL ONCOLOGY 21(12):2299-2304 Fine HA; Wen PY; Maher EA; Viscosi E; Batchelor T; Lakhani N; Figg WD; Purow BW; Borkowf CB Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas | 0 | 3 |
| 2479 | 5 | 37 | 2479 2003 JOURNAL OF CLINICAL ONCOLOGY 21(13):2551-2557 Danson S; Lorigan P; Arance A; Clamp A; Ranson M; Hodgetts J; Lomax L; Ashcroft L; Thatcher N; Middleton MR Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma | 0 | 3 |
| 2480 | 7 | 25 | 2480 2003 JOURNAL OF CLINICAL ONCOLOGY 21(14):2732-2739 Lee CK; Barlogie B; Munshi N; Zangari M; Fassas A; Jacobson J; van Rhee F; Cottler-Fox M; Muwalla F; Tricot G DTPACE: An effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma | 2 | 8 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2481 | 7 | 26 | 2481 2003 JOURNAL OF CLINICAL ONCOLOGY 21(17):3351-3356 Hwu WJ; Krown SE; Menell JH; Panageas KS; Merrell J; Lamb LA; Williams LJ; Quinn CJ; Foster T; Chapman PB; Livingston PO; Wolchok JD; Houghton AN Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma | 1 | 8 |
| 2482 | 13 | 36 | 2482 2003 JOURNAL OF CLINICAL ONCOLOGY 21(20):3770-3776 Hernberg M; Virkkunen P; Bono P; Atinen H; Maenpaa H; Joensuu H Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma | 1 | 3 |
| 2483 | 51 | 94 | 2483 2003 JOURNAL OF CLINICAL ONCOLOGY 21(23):4444-4454 Dimopoulos MA; Anagnostopoulos A; Weber D Treatment of plasma cell dyserasias with thalidomide and its derivatives | 1 | 2 |
| 2484 | 7 | 12 | 2484 2003 JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH 22(4):129-133 Bernardeschi P; Dentico P; Rossi S; Fiorentini G; Giustarini G; Turano E Low-dose thalidomide plus monthly high-dose oral dexamethasone (Thali-Dexa): Results, prognostic factors and side effects in eight patients previously treated with multiple myeloma | 0 | 0 |
| 2485 | 10 | 16 | 2485 2003 JOURNAL OF INFECTION 47(3):251-255 Roberts MTM; Mendelson M; Meyer P; Carmichael A; Lever AML The use of thalidomide in the treatment of intracranial tuberculomas in adults: two case reports | 0 | 0 |
| 2486 | 19 | 40 | 2486 2003 JOURNAL OF INFECTIOUS DISEASES 187(6):946-955 Haslett PAJ; Hanekom WA; Muller G; Kaplan G Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8(+) T cells in vitro | 0 | 0 |
| 2487 | 9 | 42 | 2487 2003 JOURNAL OF INTERFERON AND CYTOKINE RESEARCH 23(1):3-10 Bauer JA; Morrison BH; Grane RW; Jacobs BS; Borden EC; Lindner DJ IFN-alpha 2b and thalidomide synergistically inhibit tumor-induced angiogenesis | 0 | 2 |
| 2488 | 20 | 46 | 2488 2003 JOURNAL OF INVESTIGATIVE DERMATOLOGY 121(5):1060-1065 Deng L; Ding WH; Granstein RD Thalidomide inhibits tumor necrosis factor-alpha production and antigen presentation by Langerhans cells | 1 | 1 |
| 2489 | 1 | 27 | 2489 2003 JOURNAL OF MEDICAL GENETICS 40(7):473-478 Kohlhase J; Schubert L; Liebers M; Rauch A; Becker K; Mohammed SN; Newbury-Ecob R; Reardon W Mutations at the SALL4 locus on chromosome 20 result in a range of clinically overlapping phenotypes, including Okihiro syndrome, Holt-Oram syndrome, acro-renal-ocular syndrome, and patients previously reported to represent thalidomide embryopathy | 0 | 2 |
| 2490 | 11 | 25 | 2490 2003 JOURNAL OF MEDICINAL CHEMISTRY 46(18):3793-3799 Luzzio FA; Mayorov AV; Ng SSW; Kruger EA; Figg WD Thalidomide metabolites and analogues. 3. Synthesis and antiangiogenic activity of the teratogenic and TNF alpha-modulatory thalidomide analogue 2-(2,6-dioxopiperidine-3-yl)phthalimidine | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2491 | 16 | 45 | 2491 2003 JOURNAL OF MEDICINAL CHEMISTRY 46(24):5222-5229 Zhu XX; Giordano T; Yu QS; Holloway HW; Perry TA; Lahiri DK; Brossi A; Greig NH Thiothalidomides: Novel isosteric analogues of thalidomide with enhanced TNF-alpha inhibitory activity | 2 | 2 |
| 2492 | 10 | 26 | 2492 2003 JOURNAL OF NEURO-ONCOLOGY 64(3):193-201 Gelati M; Corsini E; Frigerio S; Pollo B; Broggi G; Croci D; Silvani A; Boiardi A; Salmaggi A Effects of thalidomide on parameters involved in angiogenesis: an in vitro study | 0 | 0 |
| 2493 | 4 | 4 | 2493 2003 JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 37(4):522-522 Ahmed M; El-Hadi S; Jenkins HR Thalidomide in Crohn disease and the risk of peripheral neuropathy | 0 | 0 |
| 2494 | 2 | 5 | 2494 2003 JOURNAL OF PEDIATRICS 143(5):692-694 Yasui K; Misawa Y; Shimizu T; Komiyama A; Kawakami T; Mizoguchi M Thalidomide therapy for juvenile-onset entero-Behcet disease | 0 | 0 |
| 2495 | 3 | 29 | 2495 2003 JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS 31(1):19-27 Li JY; Jaworsky MS; Stirling DI The determination of a potential impurity in Thalidomide drug substance and product by HPLC with indirect UV detection | 0 | 1 |
| 2496 | 9 | 39 | 2496 2003 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 305(3):1222-1232 Schafer PH; Gandhi AK; Loveland MA; Chen RS; Man HW; Schnetkamp PPM; Wolbring G; Govinda S; Corral LG; Payvandi F; Muller GW; Stirling DI Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs | 3 | 4 |
| 2497 | 13 | 23 | 2497 2003 JOURNAL OF PHARMACY AND PHARMACOLOGY 55(12):1701-1706 Eriksson T; Hoglund P; Turesson I; Waage A; Don BR; Vu J; Scheffler M; Kaysen GA Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis | 3 | 3 |
| 2498 | 19 | 32 | 2498 2003 JOURNAL OF RHEUMATOLOGY 30(12):2627-2631 Wei JCC; Chan TW; Lin HS; Huang F; Chou CT Thalidomide for severe refractory ankylosing spondylitis: A 6-month open-label trial | 0 | 1 |
| 2499 | 10 | 14 | 2499 2003 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 48(4):548-552 Hall VC; El-Azhary RA; Bouwhuis S; Rajkumar SV Dermatologic side effects of thalidomide in patients with multiple myeloma | 3 | 4 |
| 2500 | 9 | 12 | 2500 2003 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 48(5):S89-S91 Alfadley A; Al Rayes H; Hussein W; Al Dalaan A; Al-Aboud K Thalidomide for treatment of severe generalized discoid lupus lesions in two patients with systemic lupus erythematosus | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2501 | 11 | 52 | 2501 2003 JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION 10(3):252-259 Weeber M; Vos R; Klein H; de Jong-van den Berg LTW; Aronson AR; Molema G Generating hypotheses by discovering implicit associations in the literature: A case report of a search for new potential therapeutic uses for thalidomide. | 0 | 4 |
| 2502 | 0 | 0 | 2502 2003 JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 14:807A-807A Yaqub MS Acute renal failure in multiple myeloma patient receiving thalidomide and zoledronic acid infusion. | 0 | 0 |
| 2503 | 0 | 0 | 2503 2003 JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION 222(3):273-273 [Anon] Veterinary use of thalidomide forbidden by FDA | 0 | 0 |
| 2504 | 6 | 10 | 2504 2003 JOURNAL OF THROMBOSIS AND HAEMOSTASIS 1(3):421-422 Barbui T; Falanga A Thalidomide and thrombosis in multiple myeloma | 1 | 1 |
| 2505 | 8 | 21 | 2505 2003 JOURNAL OF THROMBOSIS AND HAEMOSTASIS 1(3):445-449 Minnema MC; Fijnheer R; De Groot PG; Lokhorst HM Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment | 2 | 2 |
| 2506 | 8 | 12 | 2506 2003 JOURNAL OF THROMBOSIS AND HAEMOSTASIS 1(12):2691-2692 Arkel YS; Ku DHW; Thurston AL The effect of thalidomide on tissue factor activity in Mono Mac 6 cells and the relationship to tumor necrosis factor (TNF)- alpha-stimulated cells | 0 | 0 |
| 2507 | 0 | 0 | 2507 2003 JOURNAL OF UROLOGY 169(4):233-233 Clark PE; Hall MC; Ridenhour KP; Stindt D; Patton SE; Brinkley W; Das S; Torti FM Phase II trial of thalidomide and interferon-alpha in advanced renal cell carcinoma | 0 | 0 |
| 2508 | 0 | 0 | 2508 2003 LANCET ONCOLOGY 4(2):70-70 Bonn D Thalidomide: no benefit in myelofibrosis with myeloid metaplasia | 0 | 0 |
| 2509 | 0 | 0 | 2509 2003 LANCET ONCOLOGY 4(12):713-713 Habeck M Australia approves thalidomide | 0 | 0 |
| 2510 | 9 | 20 | 2510 2003 LEPROSY REVIEW 74(3):206-214 Tadesse A; Taye E; Sandoval F; Shannow EJ Thalidomide does not modify the ability of cells in leprosy patients to incorporate [H-3]-thymidine when incubated with M-leprae antigens | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2511 | 3 | 20 | 2511 2003 LEPROSY REVIEW 74(3):286-288 Pannikar V The return of thalidomide: new uses and renewed concerns | 0 | 1 |
| 2512 | 7 | 32 | 2512 2003 LEPROSY REVIEW 74(3):288-290 Pereira GFM On thalidomide and VMO policies | 0 | 0 |
| 2513 | 6 | 28 | 2513 2003 LEPROSY REVIEW 74(3):290-294 Lockwood D; Bryceson A The return of thalidomide: new uses and renewed concerns - reply | 0 | 2 |
| 2514 | 0 | 0 | 2514 2003 LEPROSY REVIEW 74(3):294-295 Naafs B The return of thalidomide: new uses and renewed concerns - reply | 0 | 1 |
| 2515 | 8 | 17 | 2515 2003 LEUKEMIA 17(1):41-44 Lentzsch S; LeBlanc R; Podar K; Davies F; Lin B; Hideshima T; Catley L; Stirling DI; Anderson KC Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo | 7 | 16 |
| 2516 | 12 | 32 | 2516 2003 LEUKEMIA 17(4):775-779 Rajkumar SV; Gertz MA; Lacy MQ; Dispenzieri A; Fonseca R; Geyer SM; Iturria N; Kumar S; Lust JA; Kyle RA; Greipp PR; Witzig TE Thalidomide as initial therapy for early-stage myeloma | 11 | 18 |
| 2517 | 5 | 8 | 2517 2003 LEUKEMIA 17(6):1200-1202 Strupp C; Hildebrandt B; Germing U; Haas R; Gattermann N Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome | 0 | 1 |
| 2518 | 5 | 8 | 2518 2003 LEUKEMIA 17(8):1669-1670 Visani G; Mele A; Malagola M; Isidori A; Finelli C; Piccaluga PP Sequential combination of thalidomide and erythropoietin determines transfusion independence and disease control in idiopathic myelofibrosis previously insensitive to both drugs used as single agents | 1 | 1 |
| 2519 | 10 | 11 | 2519 2003 LEUKEMIA 17(9):1914-1915 Damaj G; Lefrere F; Delarue R; Varet B; Furman R; Hermine O Thalidomide therapy induces response in relapsed mantle cell lymphoma | 0 | 0 |
| 2520 | 3 | 8 | 2520 2003 LEUKEMIA 17(10):2056-2057 Dalle JH; Leblond P; Decouvelaere A; Yakoub-Agha I; Preudhomme C; Nelken B; Mazingue F Efficacy of thalidomide in a child with histiocytic sarcoma following allogeneic bone marrow tranplantation for T-ALL | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2521 | 3 | 6 | 2521 2003 LEUKEMIA 17(11):2237-2238 Mehta P; Hussein M Thalidomide as anti-inflammatory therapy for multiple myeloma | 0 | 0 |
| 2522 | 2 | 6 | 2522 2003 LEUKEMIA 17(11):2238-2238 Rajkumar SV; Witzig TE Thalidomide as anti-inflammatory therapy for multiple myeloma - Reply | 0 | 0 |
| 2523 | 13 | 57 | 2523 2003 LEUKEMIA & LYMPHOMA 44(2):291-298 Ribas C; Colleoni GWB Advances in the treatment of multiple myeloma: The role of thalidomide | 0 | 1 |
| 2524 | 12 | 13 | 2524 2003 LEUKEMIA & LYMPHOMA 44(6):989-991 Abdalla SH; Mahmoud S Thalidomide in relapsed or refractory multiple myeloma: How much and for how long? | 1 | 1 |
| 2525 | 1 | 6 | 2525 2003 LEUKEMIA & LYMPHOMA 44(6):1081-1082 Andretta C; Catalano L; Pace L; Fonti R; Annunziata G; Rotoli B 99mTc-sestaMIBI scintigraphy in thalidomide-treated refractory or relapsed multiple myeloma patients | 0 | 1 |
| 2526 | 30 | 38 | 2526 2003 LEUKEMIA & LYMPHOMA 44(7):1141-1146 Flowers MED; Martin PJ Evaluation of thalidomide for treatment or prevention of chronic graft-versus-host disease | 0 | 0 |
| 2527 | 12 | 17 | 2527 2003 LEUKEMIA & LYMPHOMA 44(7):1147-1149 Wechalekar AD; Chen CI; Sutton D; Reece D; Voralia M; Stewart AK Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma | 1 | 1 |
| 2528 | 19 | 36 | 2528 2003 LEUKEMIA & LYMPHOMA 44(9):1489-1493 Steins MB; Bieker R; Padro T; Kessler T; Kienast J; Berdel WE; Mesters RM Thalidomide for the treatment of acute myeloid leukemia | 0 | 0 |
| 2529 | 12 | 18 | 2529 2003 LEUKEMIA & LYMPHOMA 44(11):1943-1946 Kees M; Dimou G; Sillaber C; Drach J; Ackermann J; Lechner K; Gisslinger H Low dose thalidomide in patients with relapsed or refractory multiple myeloma | 0 | 0 |
| 2530 | 12 | 27 | 2530 2003 LEUKEMIA RESEARCH 27(10):909-914 Schey SA; Cavenagh J; Johnson R; Child JA; Oakervee H; Jones RW An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2531 | 7 | 10 | 2531 2003 LUPUS 12(9):723-724 Tektonidou MG; Vlachoyiannopoulos PG Antiphospholipid syndrome triggered by thalidomide in a patient with discoid lupus erythematosus | 0 | 0 |
| 2532 | 23 | 39 | 2532 2003 MAYO CLINIC PROCEEDINGS 78(1):34-39 Kumar S; Gertz MA; Dispenzieri A; Lacy MQ; Geyer SM; Iturria NL; Fonseca R; Hayman SR; Lust JA; Kyle RA; Greipp PR; Witzig TE; Rajkumar SV Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma | 9 | 20 |
| 2533 | 1 | 11 | 2533 2003 MEDICAL HYPOTHESES 60(4):513-514 Namazi MR The potential efficacy of thalidomide in the treatment of recalcitrant alopecia areata | 0 | 0 |
| 2534 | 1 | 2 | 2534 2003 MEDICAL JOURNAL OF AUSTRALIA 178(8):413-413 Elwood JM Thalidomide and cancer? | 0 | 0 |
| 2535 | 5 | 25 | 2535 2003 MEDICAL ONCOLOGY 20(4):397-401 Fraiman G; Ganti AK; Potti A; Mehdi S Angiosarcoma of the small intestine - Possible role for thalidomide? | 0 | 0 |
| 2536 | 12 | 35 | 2536 2003 MOLECULAR PHARMACOLOGY 64(2):415-420 Drucker L; Uziel O; Tohami T; Shapiro H; Radnay J; Yarkoni S; Lahav M; Lishner M Thalidomide down-regulates transcript levels of GC-rich promoter genes in multiple myeloma | 0 | 1 |
| 2537 | 7 | 10 | 2537 2003 NEUROLOGY 60(1):130-132 Gupta A; Cohen BH; Ruggieri P; Packer RJ; Phillips PC Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1 | 1 | 2 |
| 2538 | 4 | 7 | 2538 2003 NEUROLOGY 60(5):877-878 Giannini F; Volpi N; Rossi S; Passero S; Fimiani M; Cerase A Thalidomide-induced neuropathy: a ganglionopathy? | 3 | 3 |
| 2539 | 2 | 3 | 2539 2003 NEW ENGLAND JOURNAL OF MEDICINE 348(18):1821-1822 Morgan AE; Smith WK; Levenson JL Reversible dementia due to thalidomide therapy for multiple myeloma | 1 | 1 |
| 2540 | 3 | 31 | 2540 2003 ONCOLOGIST 8:39-45 Hussein MA Modifications to therapy for multiple myeloma: Pegylated liposomal doxorubicin in combination with vincristine, reduced-dose dexamethasone, and thalidomide | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2541 | 15 | 44 | 2541 2003 ONCOLOGY 65(3):242-249 Hsu C; Chen CN; Chen LT; Wu CY; Yang PM; Lai MY; Lee PH; Cheng AL Low-dose thalidomide treatment for advanced hepatocellular carcinoma | 1 | 3 |
| 2542 | 45 | 67 | 2542 2003 ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS 95(5):576-585 Hegarty A; Hodgson T; Porter S Thalidomide for the treatment of recalcitrant oral Crohn's disease and orofacial granulomatosis | 1 | 2 |
| 2543 | 20 | 25 | 2543 2003 ORGANIC LETTERS 5(16):2865-2867 Capitosti SM; Hansen TP; Brown ML Facile synthesis of an azido-labeled thalidomide analogue | 0 | 1 |
| 2544 | 11 | 22 | 2544 2003 PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS 33:15-18 Rodeghiero F; Elice F Thalidomide and thrombosis | 0 | 1 |
| 2545 | 1 | 26 | 2545 2003 PEDIATRIC NEUROLOGY 29(2):151-156 Marjanovic BD; Stojanov LM; Zdravkovic DS; Kravljanac RM; Djordjevic MS Rasmussen syndrome and long-term response to thalidomide | 0 | 0 |
| 2546 | 0 | 0 | 2546 2003 PHARMACOPSYCHIATRY 36(5):263-264 Schuld A; Hinze-Selch D; Haack M; Dalal MA; Himmerich H; Lancel M; Pollmacher T Sleep changes following chlorpromazine, clozapine, olanzapine or thalidomide in healthy subjects - First results from a double-blind, placebocontrolled study | 0 | 0 |
| 2547 | 15 | 21 | 2547 2003 PHARMACOTHERAPY 23(3):315-318 Horne MK; Figg WD; Arlen P; Gulley J; Parker C; Lakhani N; Parnes H; Dahut WL Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer | 3 | 4 |
| 2548 | 43 | 78 | 2548 2003 PHARMACOTHERAPY 23(4):481-493 Okafor MC Thalidomide for erythema nodosum leprosum and other applications | 0 | 0 |
| 2549 | 10 | 37 | 2549 2003 PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE 19(6):272-280 Lu KQ; Brenneman S; Burns R; Vink A; Gaines E; Haake A; Gaspari A Thalidomide inhibits UVB-induced mouse keratinocyte apoptosis by both TNF-alpha-dependent and TNF-alpha-independent pathways | 0 | 0 |
| 2550 | 73 | 77 | 2550 2003 POSTGRADUATE MEDICAL JOURNAL 79(929):127-132 Gordon JN; Goggin PM Thalidomide and its derivatives: emerging from the wilderness | 0 | 3 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2551 | 8 | 11 | 2551 2003 PRESSE MEDICALE 32(40):1894-1898 Brocvielle H; Muret P; Plenat E; Kantelip JP; Humbert P Management of a patient receiving thalidomide | 0 | 0 |
| 2552 | 10 | 48 | 2552 2003 RHEUMATIC DISEASE CLINICS OF NORTH AMERICA 29(3):481-+ Davis JC; Huang F; Maksymowych W New therapies for ankylosing spondylitis: etanercept, thalidomide, and pamidronate | 0 | 0 |
| 2553 | 43 | 95 | 2553 2003 SCHMERZ 17(3):204-+ Peuckmann V; Strumpf M; Zenz M; Bruera E Novel potential uses of thalidomide in the management of pain? A review of the literature | 0 | 0 |
| 2554 | 7 | 20 | 2554 2003 SEMINARS IN HEMATOLOGY 40(4):1-2 Barlogie B Introduction: Thalidomide and the IMiDs in multiple myeloma | 0 | 0 |
| 2555 | 12 | 17 | 2555 2003 SEMINARS IN HEMATOLOGY 40(4):3-7 Alexanian R; Weber D; Anagnostopoulos A; Delasalle K; Wang M; Rankin K Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma | 0 | 0 |
| 2556 | 14 | 23 | 2556 2003 SEMINARS IN HEMATOLOGY 40(4):8-16 Dimopoulos MA; Anagnostopoulos A Thalidomide in relapsed/refractory multiple myeloma: Pivotal trials conducted outside the United States | 0 | 0 |
| 2557 | 10 | 33 | 2557 2003 SEMINARS IN HEMATOLOGY 40(4):17-22 Rajkumar SV Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/indolent disease | 0 | 0 |
| 2558 | 11 | 14 | 2558 2003 SEMINARS IN HEMATOLOGY 40(4):33-38 Barlogie B Thalidomide and CC-5013 in multiple myeloma: The University of Arkansas experience | 0 | 0 |
| 2559 | 6 | 25 | 2559 2003 SEMINARS IN ONCOLOGY 30(2):265-269 Dimopoulos MA; Tsatalas C; Zomas A; Hamilos G; Panayiotidis P; Margaritis D; Matsouka C; Economopoulos T; Anagnostopoulos N Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone | 2 | 3 |
| 2560 | 7 | 29 | 2560 2003 SEMINARS IN ONCOLOGY 30(2):270-274 Coleman M; Leonard J; Lyons L; Szelenyi H; Niesvizky R Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone | 3 | 5 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2561 | 8 | 12 | 2561 2003 SKIN PHARMACOLOGY AND APPLIED SKIN PHYSIOLOGY 16(2):123-129 Hadgraft J; Goosen C; du Plessis J; Flynn G Predicting the dermal absorption of thalidomide and its derivatives | 0 | 0 |
| 2562 | 77 | 104 | 2562 2003 SWISS MEDICAL WEEKLY 133(5-6):77-87 von Moos R; Stolz R; Cerny T; Gillessen S Thalidomide: from tragedy to promise | 1 | 1 |
| 2563 | 4 | 19 | 2563 2003 SYNTHETIC COMMUNICATIONS 33(8):1375-1382 Chang MY; Chen ST; Chang NC A synthesis of racemic thalidomide | 0 | 4 |
| 2564 | 7 | 25 | 2564 2003 WORLD JOURNAL OF SURGERY 27(10):1119-1123 Mall JW; Schwenk W; Philipp AW; Buttemeyer R; Pollmann C Intraperitoneal administration of the angiogenesis inhibitor thalidomide does not impair anastomotic healing following large bowel resection in a rabbit model | 0 | 0 |
| 2565 | 12 | 23 | 2565 2003 XENOTRANSPLANTATION 10(5):470-474 Yamamoto S; Cooper DKC An investigation of the effect of thalidomide on anti-gal antibody production in baboons | 0 | 0 |
| 2566 | 12 | 63 | 2566 2004 ACTA NEUROBIOLOGIAE EXPERIMENTALIS 64(1):1-9 Greig NH; Giordano T; Zhu XX; Yu QS; Perry TA; Holloway HW; Brossi A; Rogers JT; Sambamurti K; Lahiri DK Thalidomide-based TNF-alpha inhibitors for neurodegenerative diseases | 0 | 0 |
| 2567 | 6 | 22 | 2567 2004 ACTA NEUROLOGICA SCANDINAVICA 109(3):188-193 Isoardo G; Bergui M; Durelli L; Barbero P; Boccadoro M; Bertola A; Ciaramitaro P; Palumbo A; Bergamasco B; Cocito D Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features | 0 | 0 |
| 2568 | 3 | 6 | 2568 2004 ACTA ONCOLOGICA 43(2):215-216 Ribas C; Colleoni G; Almeida M; Duch CR; Ohashi C; Segreto R; Silva MR Response of plasmacytomas to low-dose thalidomide in a patient with refractory multiple myeloma | 0 | 0 |
| 2569 | 10 | 60 | 2569 2004 ALIMENTARY PHARMACOLOGY & THERAPEUTICS 19(1):79-88 Austin AS; Mahida YR; Clarke D; Ryder SD; Freeman JG A pilot study to investigate the use of oxpentifylline (pentoxifylline) and thalidomide in portal hypertension secondary to alcoholic cirrhosis | 0 | 0 |
| 2570 | 15 | 16 | 2570 2004 AMERICAN JOURNAL OF CARDIOLOGY 93(8):1052-1055 Fahdi IE; Gaddam V; Saucedo JF; Kishan CV; Vyas K; Deneke MG; Razek H; Thorn B; Bissett JK; Anaisse E; Barlogie B; Mehta JL Bradycardia during therapy for multiple myeloma with thalidomide | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2571 | 2 | 5 | 2571 2004 AMERICAN JOURNAL OF HEMATOLOGY 75(3):176-177 Jung CP; Emmerich B; Goebel FD; Bogner JR Successful treatment of a patient with HIV-associated multicentric castleman disease (MCD) with thalidomide | 0 | 0 |
| 2572 | 3 | 15 | 2572 2004 AMERICAN JOURNAL OF HEMATOLOGY 76(1):66-68 Sinisalo M; Hietaharju A; Sauranen J; Wirta O Thalidomide in POEMS syndrome: Case report | 0 | 0 |
| 2573 | 18 | 33 | 2573 2004 AMERICAN JOURNAL OF VETERINARY RESEARCH 65(5):659-664 Farese JR; Fox LE; Detrisac CJ; Van Gilder JA; Roberts SL; Baldwin JA Effect of thalidomide on growth and metastasis of canine osteosarcoma cells after xenotransplantation in athymic mice | 0 | 0 |
| 2574 | 18 | 31 | 2574 2004 ANNALS OF HEMATOLOGY 83(7):467-470 Witzens M; Moehler T; Neben K; Fruehauf S; Hartschuh W; Ho AD; Goldschmidt H Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide | 0 | 0 |
| 2575 | 11 | 28 | 2575 2004 ANNALS OF ONCOLOGY 15(1):134-138 Zervas K; Dimopoulos MA; Hatzicharissi E; Anagnostopoulos A; Papaioannou A; Mitsouli C; Panagiotidis P; Korantzis J; Tzilianos M; Maniatis A; Greek Myeloma Study Grp Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study | 0 | 0 |
| 2576 | 3 | 3 | 2576 2004 ANNALS OF ONCOLOGY 15(1):176-177 Kasper B; Moehler T; Neben K; Ho AD; Goldschmidt H Combination therapy of Thalidomide and Peginterferon in patients with progressive multiple myeloma | 0 | 0 |
| 2577 | 5 | 5 | 2577 2004 ANNALS OF ONCOLOGY 15(3):537-537 Fuente N; Mane JM; Barcelo R; Munoz A; Perez-Hoyos T; Lopez-Vivanco G Tumor lysis syndrome in a multiple myeloma treated with thalidomide | 0 | 0 |
| 2578 | 12 | 23 | 2578 2004 ANNALS OF PHARMACOTHERAPY 38(5):808-811 Sayarlioglu M; Kotan MC; Topcu N; Bayram I; Arslanturk H; Gul A Treatment of recurrent perforating intestinal ulcers with thalidomide in Behcet's disease | 0 | 0 |
| 2579 | 29 | 91 | 2579 2004 ANTIOXIDANTS & REDOX SIGNALING 6(1):1-14 Hansen JM; Harris C A novel hypothesis for thalidomide-induced limb teratogenesis: Redox misregulation of the NF-kappa B pathway | 0 | 0 |
| 2580 | 10 | 44 | 2580 2004 ARCHIVES OF DERMATOLOGY 140(3):277-280 Caradona S; Jacobe H Thalidomide as a potential treatment for scleromyxedema | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2581 | 30 | 47 | 2581 2004 ARCHIVES OF DERMATOLOGY 140(7):845-849 Maurer T; Poncelet A; Berger T Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects - Efficacy and risk of neuropathy | 0 | 0 |
| 2582 | 11 | 36 | 2582 2004 ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY 24(5):885-891 Park SJ; Kim HS; Yang HM; Park KW; Youn SW; Jeon SI; Kim DH; Koo BK; Chae IH; Choi DJ; Oh BH; Lee MM; Park YB Thalidomide as a potent inhibitor of neointimal hyperplasia after balloon injury in rat carotid artery | 0 | 0 |
| 2583 | 5 | 11 | 2583 2004 ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH 51(3):505-506 Pillemer SR; Leakan RA; Sankar V; Manny J; Baum BJ; Smith J; Chaudhry U; Fox PC; Radfar L; Ligier S; Brennan MT Prominent adverse effects of thalidomide in primary Sjogren's syndrome | 0 | 0 |
| 2584 | 0 | 0 | 2584 2004 BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 10(2):73-73 Grosskreutz CL; Egan R; Scigliano E; Fruchtman SM; Isola LM Thalidomide maintenance after autologous stem cell transplantation for multiple myeloma | 0 | 0 |
| 2585 | 12 | 43 | 2585 2004 BIOORGANIC & MEDICINAL CHEMISTRY 12(2):327-336 Capitosti SM; Hansen TP; Brown ML Thalidomide analogues demonstrate dual inhibition of both angiogenesis and prostate cancer | 0 | 0 |
| 2586 | 14 | 35 | 2586 2004 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 14(2):421-425 Perino S; Contino-Pepin C; Satchi-Fainaro R; Butterfield C; Pucci B Inhibition of angiogenesis by THAM-derived cotelomers endowed with thalidomide moieties | 0 | 0 |
| 2587 | 6 | 31 | 2587 2004 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 14(16):4141-4145 Noguchi T; Sano H; Shimazawa R; Tanatani A; Miyachi H; Hashimoto Y Phenylhomophthalimide-type NOS inhibitors derived from thalidomide | 0 | 0 |
| 2588 | 27 | 47 | 2588 2004 BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY 71(1):1-16 Teo SK; Denny KH; Stirling DI; Thomas SD; Morseth SL; Hoberman AM Effects of thalidomide on reproductive function and early embryonic development in male and female New Zealand white rabbits | 0 | 0 |
| 2589 | 0 | 0 | 2589 2004 BONE 34:S97-S97 Spencer A; Roberts A; Bailey M; Schran H; Lynch K Safety and pharmacokinetic analysis of zoledronic acid in a multicentre randomised trial of post-transplant thalidomide maintenance therapy for multiple myeloma | 0 | 0 |
| 2590 | 0 | 0 | 2590 2004 BONE MARROW TRANSPLANTATION 33:S156-S156 Yakoub-Agha I; Mohty M; Attal M; Marit G; Bulabois C; Sotto JJ; Gratecos N; Rio B; Vernant JP; Facon T; Jouet JP; Intergrp Francophne Myelome & SGFM Thalidomide as salvage therapy for relapsed multiple myeloma after allogeneic stem cell transplantation | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2591 | 0 | 0 | 2591 2004 BONE MARROW TRANSPLANTATION 33:S156-S157 Hardan I; Kneller A; Shimoni A; Berkowicz M; Avigdor A; Yeshurun M; Raanani P; Davidowich Y; Shemtov N; Ben Bassat I; Nagler A Salvage of multiple myeloma patients relapse after an autologous stem cell transplantation, in the era of thalidomide and reduced-intensity allogeneic stem cell transplantation | 0 | 0 |
| 2592 | 0 | 0 | 2592 2004 BONE MARROW TRANSPLANTATION 33:S160-S161 Ciepluch H; Knopinska-Posluszny W; Czyz J; Hellmann A Employment of autologous transplantation of progenitor cells following effective treatment with thalidomide of patients with multiple myeloma resistant to conventional chemotherapy | 0 | 0 |
| 2593 | 0 | 0 | 2593 2004 BONE MARROW TRANSPLANTATION 33:S161-S161 Trojan A; Giger R; Rist N; Jager D; Taverna C Thalidomide stimulates peptide specific CD8+T-cells against viral epitopes | 0 | 0 |
| 2594 | 0 | 0 | 2594 2004 BONE MARROW TRANSPLANTATION 33:S162-S162 Hoyer B; Fenk R; Steidl U; Germing U; Haas R; Kobbe G Treatment of patients with multiple myeloma in first relapse after high-dose chemotherapy with single agent thalidomide - duration of first remission is the major prognostic factor for EFS and OS | 0 | 0 |
| 2595 | 0 | 0 | 2595 2004 BONE MARROW TRANSPLANTATION 33:S165-S165 Offidani M; Marconi M; Corvatta L; Malerba L; Olivieri A; Mele A; Galieni P; Centurioni R; Alesiani F; Candela M; Leoni P Combination thalidomide, doxil and dexamethasone as salvage therapy for patients relapsed after tandem autotransplant | 0 | 0 |
| 2596 | 0 | 0 | 2596 2004 BONE MARROW TRANSPLANTATION 33:S356-S356 Alegre A; Martinez-Chamorro C; Escudero A; Aguado B; Osorio S; Nistal S; Cordoba R; Gil-Fernandez J; Sanchez-Godoy P; Burgaleta C; Casado F; Fernandez-Ranada JM Maintenance treatment with bisphosphonates plus interferon plus dexamethasone plus thalidomide (quadruple maintenance) after autologous peripheral blood stem cell transplantion in multiple myeloma: preliminary results | 0 | 0 |
| 2597 | 3 | 38 | 2597 2004 BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH 37(4):485-492 Arruda MSP; Richini VB; Oliveira SMA; Vilani-Moreno FR Experimental murine mycobacteriosis: evaluation of the functional activity of alveolar macrophages in thalidomide-treated mice | 0 | 0 |
| 2598 | 32 | 40 | 2598 2004 BRITISH JOURNAL OF CANCER 90(5):955-961 Bartlett JB; Michael A; Clarke IA; Dredge K; Nicholson S; Kristeleit H; Polychronis A; Pandha H; Muller GW; Stirling DI; Zeldis J; Dalgleish AG Phase 1 study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers | 1 | 1 |
| 2599 | 0 | 0 | 2599 2004 BRITISH JOURNAL OF HAEMATOLOGY 125:20-20 Morris TCM; Hull DR; Boyd C; Jones FCG; Kettle PJ; Drake M; McLoughlin R; Quinn J Clarithromycin, dexamethasone and low dose thalidomide (CDT) is effective therapy in relapsed/refractory myeloma and useful in patients with cytopenias | 0 | 0 |
| 2600 | 4 | 5 | 2600 2004 BRITISH JOURNAL OF HAEMATOLOGY 125(1):96-97 Fakhouri F; Guerraoui H; Presne C; Peltier J; Delarue R; Muret P; Knebelmann B Thalidomide in patients with multiple myeloma and renal failure | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2601 | 11 | 15 | 2601 2004 BRITISH JOURNAL OF HAEMATOLOGY 125(2):149-155 Waage A; Gimsing P; Juliusson G; Turesson I; Gulbrandsen N; Eriksson T; Hjorth M; Nielsen JL; Lenhoff S; Westin J; Wisloff F; Nordic Myeloma Study Grp Early response predicts thalidomide efficiency in patients with advanced multiple myeloma | 0 | 0 |
| 2602 | 15 | 15 | 2602 2004 CANADIAN JOURNAL OF GASTROENTEROLOGY 18(2):101-104 Hershfield NB Disappearance of Chron's ulcers in the terminal ileum after thalidomide therapy | 0 | 0 |
| 2603 | 2 | 3 | 2603 2004 CANADIAN JOURNAL OF GASTROENTEROLOGY 18(6):419-419 Cohen LB Re: Disappearance of Crohn's ulcers in the terminal ileum after thalidomide therapy. Can J Gastroenterol 2004; 18(2): 101-104. | 0 | 0 |
| 2604 | 0 | 0 | 2604 2004 CANADIAN JOURNAL OF GASTROENTEROLOGY 18(6):419-419 Hershfield NB Re: Disappearance of Crohn's ulcers in the terminal ileum after thalidomide therapy. Can J Gastroenterol 2004; 18(2): 101-104. Response | 0 | 0 |
| 2605 | 7 | 8 | 2605 2004 CANCER 100(6):1186-1189 Pro B; Younes A; Albitar M; Dang NH; Samaniego F; Romaguera J; McLaughlin P; Hagemeister FB; Rodriguez MA; Clemons M; Cabanillas F Thalidomide for patients with recurrent lymphoma | 0 | 0 |
| 2606 | 13 | 28 | 2606 2004 CANCER CHEMOTHERAPY AND PHARMACOLOGY 53(5):377-383 Chung F; Wang LCS; Kestell P; Baguley BC; Ching LM Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor | 1 | 1 |
| 2607 | 10 | 33 | 2607 2004 CELL BIOLOGY INTERNATIONAL 28(3):237-242 Ergun MA; Konac E; Erbas D; Ekmekci A Apoptosis and nitric oxide release induced by thalidomide, gossypol and dexamethasone in cultured human chronic myelogenous leukemic K-562 cells | 0 | 1 |
| 2608 | 6 | 23 | 2608 2004 CHEMICAL & PHARMACEUTICAL BULLETIN 52(4):498-499 Shimazawa R; Sano H; Tanatani A; Miyachi H; Hashimoto Y Thalidomide as a nitric oxide synthase inhibitor and its structural development | 1 | 1 |
| 2609 | 5 | 17 | 2609 2004 CHIRALITY 16:S36-S39 Nakanishi T; Yamakawa N; Asahi T; Shibata N; Ohtani B; Osaka T Chiral discrimination between thalidomide enantiomers using a solid surface with two-dimensional chirality | 0 | 0 |
| 2610 | 2 | 13 | 2610 2004 CLINICAL AND EXPERIMENTAL DERMATOLOGY 29(3):268-270 Eisman S; Orteu CH Recalcitrant erosive flexural lichen planus: successful treatment with a combination of thalidomide and 0.1% tacrolimus ointment | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2611 | 10 | 20 | 2611 2004 CLINICAL CANCER RESEARCH 10(12):4192-4197 Ng SSW; Macpherson GR; Gutschow M; Eger K; Figg WD Antitumor effects of thalidomide analogs in human prostate cancer Xenografts implanted in immunodeficient mice | 0 | 0 |
| 2612 | 3 | 23 | 2612 2004 CLINICAL NEPHROLOGY 61(5):352-356 Menegato MA; Canelles MF; Tonutti E; Pizzolitto S Remission of nephrotic syndrome after thalidomide therapy in a patient with Castleman's disease | 0 | 0 |
| 2613 | 52 | 65 | 2613 2004 CLINICAL PHARMACOKINETICS 43(5):311-327 Teo SK; Colburn WA; Tracewell WG; Kook KA; Stirling DI; Jaworsky MS; Scheffler MA; Thomas SD; Laskin OL Clinical pharmacokinetics of thalidomide | 0 | 0 |
| 2614 | 10 | 29 | 2614 2004 CYTOKINE 26(4):145-148 Rosinol L; Cibeira MT; Segarra M; Cid MC; Filella X; Aymerich M; Rozman M; Arenillas L; Esteve J; Blade J; Montserrat E Response to thalidomide in multiple myeloma: impact of angiogenic factors | 0 | 0 |
| 2615 | 12 | 17 | 2615 2004 DERMATOLOGY 208(2):149-152 Sander CS; Kaatz M; Elsner P Successful treatment of cutaneous Langerhans cell histiocytosis with thalidomide | 0 | 0 |
| 2616 | 1 | 1 | 2616 2004 DIABETOLOGIA 47(5):963-963 Bosco AA; Lerario AC; Santos RF; Wajchenberg BL Effect of thalidomide and rosiglitazone on the prevention of diabetic retinopathy in streptozotocin-induced diabetic rats (vol 46, pg 1669, 2003) | 0 | 0 |
| 2617 | 8 | 28 | 2617 2004 DRUGS OF THE FUTURE 29(4):383-391 Hashimoto Y; Tanatani A; Nagasawa K; Miyachi H Thalidomide as a multitarget drug and its application as a template for drug design | 0 | 0 |
| 2618 | 24 | 52 | 2618 2004 DRUGS OF TODAY 40(3):197-204 Joglekar S; Levin M The promise of thalidomide: Evolving indications | 0 | 0 |
| 2619 | 16 | 28 | 2619 2004 EUROPEAN JOURNAL OF HAEMATOLOGY 72(1):52-57 Strupp C; Germing U; Scherer A; Kundgen A; Modder U; Gattermann N; Haas R Thalidomide for the treatment of idiopathic myelofibrosis | 0 | 0 |
| 2620 | 16 | 30 | 2620 2004 EUROPEAN JOURNAL OF HAEMATOLOGY 72(6):403-409 Offidani M; Corvatta L; Marconi M; Malerba L; Mele A; Olivieri A; Brunori M; Catarini M; Candela M; Capelli D; Montanari M; Rupoli S; Leoni P Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2621 | 11 | 26 | 2621 2004 EUROPEAN JOURNAL OF HAEMATOLOGY 73(2):98-103 Tosi P; Zamagni E; Cellini C; Cangini D; Tacchetti P; Tura S; Baccarani M; Cavo M Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure | 0 | 0 |
| 2622 | 4 | 22 | 2622 2004 EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES 21(4):465-469 Abraham MH Hydrogen bond and other descriptors for thalidomide and its N-alkyl analogs; prediction of physicochemical and biological properties | 0 | 0 |
| 2623 | 0 | 37 | 2623 2004 EXPERIMENTAL BRAIN RESEARCH 156(3):333-341 Stoeckel MC; Pollok B; Schnitzler A; Witte OW; Seitz RJ Use-dependent cortical plasticity in thalidomide-induced upper extremity dysplasia: evidence from somaesthesia and neuroimaging | 0 | 0 |
| 2624 | 42 | 78 | 2624 2004 EXPERT OPINION ON THERAPEUTIC PATENTS 14(2):215-229 Luzzio FA; Figg WD Thalidomide analogues: derivatives of an orphan drug with diverse biological activity | 0 | 0 |
| 2625 | 0 | 0 | 2625 2004 FASEB JOURNAL 18(4):A68-A68 Segarra M; Lozano E; Vilardell C; Esparza J; Izco N; Blade J; Campo E; Cid MC Thalidomide (Thd) decreases Fibronectin (FN)-induced gelatinase (MMP-2 and MMP-9) production by B lymphoid cell lines | 0 | 0 |
| 2626 | 6 | 21 | 2626 2004 GUT 53(4):609-612 Bauditz J; Schachschal G; Wedel S; Lochs H Thalidomide for treatment of severe intestinal bleeding | 0 | 0 |
| 2627 | 7 | 25 | 2627 2004 HAEMATOLOGICA 89(5):552-556 Brenne AT; Romstad LH; Gimsing P; Juliusson G; Turesson I; Romundstad P; Borset M; Sundan A; Waage A Low serum level of soluble tumor necrosis factor receptor p55 predicts response to thalidomide in advanced multiple myeloma | 0 | 0 |
| 2628 | 19 | 37 | 2628 2004 HAEMATOLOGICA 89(7):826-831 Cavo M; Zamagni E; Tosi P; Cellini C; Cangini D; Tacchetti P; Testoni N; Tonelli M; De Vivo A; Palareti G; Tura S; Baccarani M First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma | 0 | 0 |
| 2629 | 9 | 32 | 2629 2004 HAEMATOLOGICA 89(7):832-836 Rosinol L; Cibeira T; Blade J; Esteve J; Aymerich M; Rozman M; Segarra M; Cid MC; Filella X; Montserrat E Extramedullary multiple myeloma escapes the effect of thalidomide | 0 | 0 |
| 2630 | 8 | 24 | 2630 2004 HISTOCHEMISTRY AND CELL BIOLOGY 122(1):27-33 Fujita K; Asami Y; Tanaka K; Akita M; Merker HJ Anti-angiogenic effects of thalidomide: expression of apoptosis-inducible active-caspase-3 in a three-dimensional collagen gel culture of aorta | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2631 | 5 | 30 | 2631 2004 INTERNATIONAL JOURNAL OF CANCER 110(2):260-265 Kedar I; Mermershtain W; Ivgi H Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2-based therapy | 0 | 0 |
| 2632 | 17 | 25 | 2632 2004 INTERNATIONAL JOURNAL OF HEMATOLOGY 79(3):283-288 Hattori Y; Kakimoto T; Okamoto S; Sato N; Ikeda Y Thalidomide-induced severe neutropenia during treatment of multiple myeloma | 0 | 0 |
| 2633 | 9 | 19 | 2633 2004 INTERNATIONAL JOURNAL OF HEMATOLOGY 79(4):364-368 Okikawa Y; Sakai A; Takimoto Y; Noda M; Imagawa J; Katayama Y; Kuroda Y; Okita H; Fujimura K; Kimura A Progressive myeloma after thalidomide therapy in a patient with immature phenotype of myeloma (plasma) cells | 0 | 0 |
| 2634 | 13 | 26 | 2634 2004 JOURNAL OF CHILD NEUROLOGY 19(4):250-257 Schoeman JF; Springer P; van Rensburg AJ; Swanevelder S; Hanekom WA; Haslett PAJ; Kaplan G Adjunctive thalidomide therapy for childhood tuberculous meningitis: Results of a randomized study | 0 | 0 |
| 2635 | 8 | 24 | 2635 2004 JOURNAL OF CLINICAL ONCOLOGY 22(3):424-431 Marchetti M; Barosi G; Balestri F; Viarengo G; Gentili S; Barulli S; Demory JL; Ilariucci F; Volpe A; Bordessoule D; Grossi A; Le Bousse-Kerdiles MC; Caenazzo A; Pecci A; Falcone A; Broccia G; Bendotti C; Bauduer F; Buccisano F; Dupriez B Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: A phase II trial | 0 | 0 |
| 2636 | 9 | 42 | 2636 2004 JOURNAL OF CLINICAL ONCOLOGY 22(13):2532-2539 Dahut WL; Gulley JL; Arlen PM; Liu Y; Fedenko KM; Steinberg SM; Wright JJ; Parnes H; Chen CC; Jones E; Parker CE; Linehan WM; Figg WD Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer | 0 | 0 |
| 2637 | 0 | 1 | 2637 2004 JOURNAL OF CLINICAL ONCOLOGY 22(14):2973-2973 Kumar Thalidomide: Current role in the treatment of non-plasma cell malignancies (vol 22, pg 2477, 20040 | 0 | 0 |
| 2638 | 25 | 42 | 2638 2004 JOURNAL OF IMMUNOLOGY 172(8):5103-5109 Gockel HR; Lugering A; Heidemann J; Schmidt M; Domschke W; Kucharzik T; Lugering N Thalidomide induces apoptosis in human monocytes by using a cytochrome c-dependent pathway | 0 | 0 |
| 2639 | 8 | 18 | 2639 2004 JOURNAL OF IMMUNOTHERAPY 27(4):259-264 Elaraj DM; White DE; Steinberg SM; Haworth K; Rosenberg SA; Yang JC A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma | 0 | 0 |
| 2640 | 0 | 0 | 2640 2004 JOURNAL OF INVESTIGATIVE DERMATOLOGY 122(3):A7-A7 Jin JH; Zhang W; Werth VP Thalidomide inhibits the induction of tumor necrosis factor-alpha by ultraviolet B irradiation of human keratinocytes | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2641 | 0 | 0 | 2641 2004 JOURNAL OF INVESTIGATIVE DERMATOLOGY 123(2) Heere-Ress E; Boehm J; Hoeller C; Wacheck V; Thallinger C; Wolff K; Jansen B; Pehamberger H Thalidomide combined with dacarbazine enhances the anti-tumor activity in a human melanoma xenotransplantation model | 0 | 0 |
| 2642 | 0 | 0 | 2642 2004 JOURNAL OF INVESTIGATIVE MEDICINE 52(2):S403-S403 Segarra M; Lozano E; Vilardell C; Esparza J; Izco N; Blade J; Campo E; Cid MC Thalidomide decreases fibronectin-induced gelatinase (MMP-2 and MMP-9) production by B lymphoid cell lines. | 0 | 0 |
| 2643 | 15 | 23 | 2643 2004 JOURNAL OF MEDICINAL CHEMISTRY 47(9):2219-2227 Lepper ER; Ng SSW; Gutschow M; Weiss M; Hauschildt S; Hecker TK; Luzzio FA; Eger K; Figg WD Comparative molecular field analysis and comparative molecular similarity indices analysis of thalidomide analogues as angiogenesis inhibitors | 0 | 0 |
| 2644 | 6 | 26 | 2644 2004 JOURNAL OF NEURO-ONCOLOGY 66(3):295-299 Piribauer M; Czech T; Dieckmann K; Birner P; Hainfellner JA; Prayer D; Fazeny-Dorner B; Weinlander G; Marosi C Stabilization of a progressive hemangioblastoma under treatment with thalidomide | 0 | 0 |
| 2645 | 8 | 30 | 2645 2004 JOURNAL OF NEURO-ONCOLOGY 67(1-2):191-200 Baumann F; Bjeljac M; Kollias SS; Baumert BG; Brandner S; Rousson V; Yonekawa Y; Bernays RL Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme | 0 | 0 |
| 2646 | 7 | 34 | 2646 2004 JOURNAL OF PERIODONTOLOGY 75(1):162-168 Lima V; Vidal FDP; Rocha FAC; Brito GAC; Ribeiro RA Effects of tumor necrosis factor-alpha inhibitors pentoxifylline and thalidomide on alveolar bone loss in short-term experimental periodontal disease in rats | 0 | 0 |
| 2647 | 20 | 27 | 2647 2004 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 310(2):571-577 Lu J; Helsby N; Palmer BD; Tingle M; Baguley BC; Kestell P; Ching LM Metabolism of thalidomide in liver microsomes of mice, rabbits, and humans | 0 | 0 |
| 2648 | 27 | 45 | 2648 2004 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 50(2):235-241 Nguyen YT; Dupuy A; Cordoliani F; Vignon-Pennamen MD; Lebbe C; Morel P; Rybojad M Treatment of cutaneous sarcoidosis with thalidomide | 0 | 0 |
| 2649 | 0 | 0 | 2649 2004 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 50(3):P78-P78 Wu JJ; Pang KR; Hsu S; Tyring SK Thalidomide: A review of new indications | 0 | 0 |
| 2650 | 13 | 23 | 2650 2004 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 51(1):126-131 Sansbury JC; Cocuroccia B; Jorizzo JL; Gubinelli E; Gisondi P; Girolomoni G Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2651 | 0 | 0 | 2651 2004 JOURNAL OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION 11(2):275A-275A Dharia SP; Steinkampf MP; Parker CR; Grubbs CJ; Crockett S The impact of thalidomide on ovarian function. | 0 | 0 |
| 2652 | 6 | 33 | 2652 2004 JOURNAL OF THROMBOSIS AND HAEMOSTASIS 2(2):327-334 Kaushal V; Kaushal GP; Melkaveri SN; Mehta P Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology | 0 | 0 |
| 2653 | 3 | 5 | 2653 2004 LANCET 363(9403):169-169 McBride W Health of thalidomide victims and their progeny | 0 | 0 |
| 2654 | 132 | 159 | 2654 2004 LANCET 363(9423):1802-1811 Franks ME; Macpherson GR; Figg WD Thalidomide | 0 | 0 |
| 2655 | 2 | 5 | 2655 2004 LANCET 363(9424):1911-1911 Crawford CL Does thalidomide have a role in leprosy? | 0 | 0 |
| 2656 | 11 | 40 | 2656 2004 LEUKEMIA 18(3):624-627 Kumar S; Witzig TE; Dispenzieri A; Lacy MQ; Wellik LE; Fonseca R; Lust JA; Gertz MA; Kyle RA; Greipp PR; Rajkumar SV Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma | 1 | 1 |
| 2657 | 27 | 54 | 2657 2004 LEUKEMIA 18(4):856-863 Garcia-Sanz R; Gonzalez-Porras JR; Hernandez JM; Polo-Zarzuela M; Sureda A; Barrenetxea C; Palomera L; Lopez R; Grande-Garcia C; Alegre A; Vargas-Pabon M; Gutierrez ON; Rodriguez JA; San Miguel JF The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma | 0 | 1 |
| 2658 | 10 | 18 | 2658 2004 LEUKEMIA & LYMPHOMA 45(1):113-116 Anagnostopoulos A; Hamilos G; Zorzou MP; Grigoraki V; Anagnostou D; Dimopoulos MA Discordant response or progression in patients with myeloma treated with thalidomide-based regimens | 0 | 0 |
| 2659 | 4 | 13 | 2659 2004 LEUKEMIA & LYMPHOMA 45(1):179-181 Baird R; van Zyl-Smit RN; Iveson A; Duddy J; Rassam S Thalidomide is highly effective in a patient with meningeal acute myeloid leukaemia | 0 | 0 |
| 2660 | 14 | 20 | 2660 2004 LEUKEMIA & LYMPHOMA 45(4):735-738 Balleari E; Ghio R; Falcone A; Musto P Possible multiple myeloma dedifferentiation following thalidomide therapy: A report of four cases | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2661 | 7 | 12 | 2661 2004 LEUKEMIA & LYMPHOMA 45(8):1711-1712 Montagut C; Bosch F; Villela L; Rosinol L; Blade J Aminoglycoside-associated severe renal failure in patients with multiple myeloma treated with thalidomide | 0 | 0 |
| 2662 | 15 | 59 | 2662 2004 LEUKEMIA RESEARCH 28(4):325-332 Musto P Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives | 0 | 0 |
| 2663 | 1 | 41 | 2663 2004 LEUKEMIA RESEARCH 28(8):791-803 Raza A; Buonamici S; Lisak L; Tahir S; Li DL; Imran M; Chaudary NI; Pervaiz H; Gallegos JA; Alvi MI; Mumtaz M; Gezer S; Venugopal P; Reddy P; Galili N; Candoni A; Singer J; Nucifora G Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression | 0 | 0 |
| 2664 | 5 | 7 | 2664 2004 LUPUS 13(6):481-482 Pagnoux C; Lutz-Zarrouk V; Michel M; Schaeffer A; Godeau B Cerebral venous thrombosis in a patient with antiphospholipid syndrome treated with thalidomide | 0 | 0 |
| 2665 | 15 | 44 | 2665 2004 MAYO CLINIC PROCEEDINGS 79(7):857-858 Silver RT Myelofibrosis: Thalidomide finds a new disease | 0 | 0 |
| 2666 | 12 | 22 | 2666 2004 MAYO CLINIC PROCEEDINGS 79(7):875-882 Richardson P; Schlossman R; Jagannath S; Alsina M; Desikan R; Blood E; Weller E; Mitsiades C; Hideshima T; Davies F; Doss D; Freeman A; Bosch J; Patin J; Knight R; Zeldis J; Dalton W; Anderson K Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: Results of an open-label Multicenter phase 2 study of efficacy, toxicity, and biological activity | 0 | 0 |
| 2667 | 21 | 42 | 2667 2004 MAYO CLINIC PROCEEDINGS 79(7):883-889 Mesa RA; Elliott MA; Schroeder G; Tefferi A Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia | 1 | 1 |
| 2668 | 59 | 83 | 2668 2004 MAYO CLINIC PROCEEDINGS 79(7):899-903 Rajkumar SV Thalidomide: Tragic past and promising future | 0 | 0 |
| 2669 | 0 | 2 | 2669 2004 MEDICAL JOURNAL OF AUSTRALIA 180(4):199-200 Crawford CL Licensing thalidomide in Australia | 0 | 0 |
| 2670 | 0 | 3 | 2670 2004 MEDICAL JOURNAL OF AUSTRALIA 180(4):200-200 Tattersall MHN Licensing thalidomide in Australia - Reply | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2671 | 5 | 5 | 2671 2004 MEDICAL JOURNAL OF AUSTRALIA 180(7):366-367 Coutsouvelis J; Corallo CE Thalidomide-induced bradycardia and its management | 0 | 0 |
| 2672 | 7 | 10 | 2672 2004 MEDICINA CLINICA 122(15):595-596 Cistero B; Sala M; Soler A; Garcia N Thalidomide in the treatment of recurrent plasmocitomas in an HIV-infected patient | 0 | 0 |
| 2673 | 10 | 32 | 2673 2004 MELANOMA RESEARCH 14(1):57-62 Pawlak WZ; Legha SS Phase II study of thalidomide in patients with metastatic melanoma | 0 | 0 |
| 2674 | 9 | 15 | 2674 2004 MICROCHEMICAL JOURNAL 77(1):1-7 Cardoso CE; Martins ROR; Aucelio RQ Evaluation of a spectrofluorimetric method for the selective determination of thalidomide in pharmaceutical tablets, urine and blood serum | 0 | 0 |
| 2675 | 21 | 45 | 2675 2004 MOLECULES AND CELLS 17(2):210-216 Kim YS; Kim JS; Jung HC; Song IS The effects of thalidomide on the stimulation of NF-kappa B activity and TNF-alpha production by lipopolysaccharide in a human colonic epithelial cell line | 0 | 0 |
| 2676 | 44 | 57 | 2676 2004 NATURE REVIEWS CANCER 4(4):314-322 Bartlett JB; Dredge K; Dalgleish AG Timeline - The evolution of thalidomide and its IMiD derivatives as anticancer agents | 1 | 1 |
| 2677 | 15 | 16 | 2677 2004 NEUROLOGY 62(12):2158-2159 Apfel SC; Zochodne DW Thalidomide neuropathy - Too much or too long? | 0 | 0 |
| 2678 | 8 | 10 | 2678 2004 NEUROLOGY 62(12):2288-2290 Briani C; Zara G; Rondinone R; Della Libera S; Ermani M; Ruggero S; Ghirardello A; Zampieri S; Doria A Thalidomide neurotoxicity - Prospective study in patients with lupus erythematosus | 1 | 1 |
| 2679 | 8 | 10 | 2679 2004 NEUROLOGY 62(12):2291-2293 Cavaletti G; Beronio A; Reni L; Ghiglione E; Schenone A; Briani C; Zara G; Cocito D; Isoardo G; Ciaramitaro P; Plasmati R; Pastorelli F; Frigo M; Piatti M; Carpo M Thalidomide sensory neurotoxicity - A clinical and neurophysiologic study | 1 | 1 |
| 2680 | 14 | 27 | 2680 2004 ONCOLOGY REPORTS 11(1):93-95 Morabito A; Fanelli M; Carillio G; Gattuso D; Sarmiento R; Gasparini G Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2681 | 14 | 24 | 2681 2004 ONKOLOGIE 27(2):150-154 Steurer M; Spizzo G; Mitterer M; Gastl G Low-dose thalidomide for multiple myeloma: Interim analysis of a compassionate use program | 0 | 0 |
| 2682 | 11 | 41 | 2682 2004 PATHOLOGY INTERNATIONAL 54(5):285-294 Du WL; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment | 0 | 0 |
| 2683 | 13 | 19 | 2683 2004 THROMBOSIS AND HAEMOSTASIS 91(4):834-836 Potenza L; Luppi M; Morselli M; Saviola A; Ferrari A; Riva G; Longo G; Marietta M; Torelli G Thrombotic complications associated with thalidomide in multiple myeloma: an old problem with new questions and quandaries in decision-making | 0 | 0 |
| 2684 | 2 | 10 | 2684 2004 TRANSPLANTATION PROCEEDINGS 36(4):1018-1020 Chaves DNB; Petroianu A; Alberti LR; Pereira WA Effects of thalidomide, cyclosporine, and diclofenac on skin allograft survival in rabbits | 0 | 0 |
| 2685 | 14 | 32 | 2685 2004 UROLOGY 63(6):1061-1065 Clark PE; Hall MC; Miller A; Ridenhour KP; Stindt D; Lovato JF; Patton SE; Brinkley W; Das S; Torti FM Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma | 0 | 0 |
Page 9: 1 2 3 4 5 6 7 8 9
Generated by: HistCite(Vlad).
Version: 2004.09.22